Bahamas

Reimbursed Care Access

As of the most recent publicly available sources, The Bahamas maintains a regulatory framework that controls most classic psychedelics under its Dangerous Drugs legislation while permitting regulated medical/pharmaceutical practice under pharmacy and health laws. Ketamine is available as a licensed anaesthetic and is used in clinical/private settings (including off‑label psychiatric use at private clinics), while esketamine (Spravato) does not appear to have an established, publicly documented national reimbursement pathway or formal national approval as a subsidized medicine. Recreational/unsanctioned supply of MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X and most other classical psychedelics remains controlled or only accessible within narrow research/clinic gray areas or through private retreat operators. Important: claims about specific scheduling are drawn from The Bahamas Dangerous Drugs Act and recent regulatory summaries; where local registers are not published online, activity such as private clinics or retreats is reported in secondary sources and may reflect enforcement/practice variation. [https://sherloc.unodc.org/cld/document/bhs/2000/the_dangerous_drugs_act_2000.html|Bahamas Dangerous Drugs Act (UNODC summary)] [https://www.bfsb-bahamas.com/legislation/miscellaneous.lasso|Bahamas legislative summaries / Pharmacy & Health references] [https://www.psilocybinalpha.com/data/worldwide-psychedelic-laws|Psychedelic Alpha – Bahamas summary].